LBLifecore Biomedical, Inc.WEWebster Equity Partners

Overview

Lifecore Biomedical, Inc. agreed to be acquired by Webster Equity Partners for $6.28 per share of common stock in cash at closing plus one non-tradable contingent value right per share, with Series A Preferred stockholders receiving the Conversion Amount in cash plus a CVR, in a transaction valued at up to $663.7 million assuming full achievement of performance milestones.

Deal rationale

The transaction is expected to support Lifecore's next phase of growth by pairing Webster Equity Partners' resources and expertise with Lifecore's CDMO capabilities to accelerate growth and pursue sustainable profitability.

Timeline

1. AnnouncedSep 28, 2026

   Deal announced.

   Filing

Valuation and terms

Advisors

Parties